India Oral Anti-Diabetic Drug Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.7 Billion |
| Market Size (2029) | USD 2.01 Billion |
| CAGR (2024 - 2029) | 3.50 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
India Oral Anti-Diabetic Drug Market Analysis
The India Oral Anti-Diabetic Drug Market size is estimated at USD 1.7 billion in 2024, and is expected to reach USD 2.01 billion by 2029, growing at a CAGR of 3.5% during the forecast period (2024-2029).
One in six people with diabetes worldwide, according to an article in "THE HINDU," is Indian. With an estimated 80 million diabetics, the country ranks second among the top 10 countries for those with the disease. In India, more than 50% of the population is at risk of developing diabetes at some point in their lives, making it a serious public health issue. Rural parts of India are also experiencing an increase in the incidence of type 2 diabetes.
After lifestyle changes, oral anti-diabetic medications play a significant role in the management of diabetes. Dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors are two novel medications that can be used alone or in combination with existing glucose-lowering medications, such as insulin, when diet and exercise alone are insufficient, and metformin is not tolerated. These drugs have different therapeutic, pharmacokinetic, and safety properties than the more established drugs.
Recently approved drugs like bromocriptine and hydroxychloroquine (hcq) have positive effects on blood sugar and HbA1C levels. Sulfonylureas (SU) were the only licensed insulin rivals until metformin was approved, and they were widely employed to treat T2DM. While there are now just three SU medications that can be prescribed.
India Oral Anti-Diabetic Drug Market Trends
Sodium-glucose Cotransport-2 (SGLT-2) inhibitor Segment Occupied the Highest Market Share in India Oral Anti-Diabetic Drugs Market in current year
In terms of revenue, the Sodium-glucose cotransport -2 (SGLT-2) inhibitor segment is anticipated to lead the India Oral Anti-Diabetic Drugs Market and post a CAGR of over 11% during the course of the forecast year.
Type 2 diabetes is treated using a group of drugs called Sodium-glucose cotransport -2 (SGLT-2) inhibitors, some of which have also been approved to treat obesity. One of its benefits is that they are less likely to cause hypoglycemia than more traditional insulin secretagogues like sulfonylureas or meglitinides. In addition to significantly lowering blood sugar, SGLT2As have significant effects on the makeup of gut bacteria, lung protection, and inflammation.
The National Health Program is divided into basic aid tiers, each of which can be specifically defined in a given place. The National Health Program is structured according to LEAs. The LEAs specify all medical assistance programs offered by the INHS to citizens, with or without a patient's income-based partial contribution.
Diabetes, a serious health disease, is one of the main issues Italian healthcare institutions are currently confronting. The progression of the disease, its rising prevalence, and the need for more treatment choices for diabetes patients have sparked the creation of novel drugs. The launch of various new products, developing international research collaborations for technical improvement, and increasing public awareness of diabetes are some of the potential opportunities for enterprises in the Indian diabetes pharmaceutical market.
Increasing Diabetes Population in India is driving the market.
Diabetes, a long-term condition, is a silent killer. Several medical professionals cautioned that patients with comorbid conditions are particularly vulnerable to the virus during the initial COVID-19 wave last year. Diabetes mellitus, generally known as diabetes, is a metabolic condition characterized by high blood sugar levels. A complete lack of insulin results in type 1 diabetes, also known as insulin-dependent diabetes mellitus.
With type 2 diabetes mellitus, the body either produces insufficient amounts of insulin or is unable to use the insulin that is produced. According to some, type 2 diabetes is a lifestyle condition. Sugary treats are a hallmark of Indian culture and are consumed during many religious festivals and old customs. It is therefore anticipated to drive the category expansion during the forecast period because of the aforementioned factors.
Unfortunately, with more patients being added each year, India has become the world's diabetes capital. This is a key source of concern for the Center as well as adding to the growing cost of healthcare on the Indian economy. The government is aware of this and appears to be acting to combat it by lowering the price of a few recently released diabetes medications. Pharma companies are also recognizing a new development opportunity by developing novel medications and therapeutic fusions.
India Oral Anti-Diabetic Drug Industry Overview
India's oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.
India Oral Anti-Diabetic Drug Market Leaders
Sanofi
Eli Lilly
Astellas
Janseen
Astrazeneca
*Disclaimer: Major Players sorted in no particular order
India Oral Anti-Diabetic Drug Market News
- October 2023: Glenmark Pharmaceuticals has announced the release of a new triple-fixed-dose combination (FDC) medication for diabetes treatment. The company, headquartered in Mumbai, has unveiled the blend of Teneligliptin, Dapagliflozin, and Metformin under the brand name Zita.
- Jan 2022: Novo Nordisk, the Danish drug maker, announced the launch of oral semaglutide in India for the treatment of type 2 diabetes.
- Nov 2022: AstraZeneca India gets approval to market anti-diabetes drug. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug Dapagliflozin indicated for diabetes patients with chronic kidney disease (CKD).
India Oral Anti-Diabetic Drug Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028)
5.1.1 Biguanides
5.1.1.1 Metformin
5.1.2 Alpha-Glucosidase Inhibitors
5.1.2.1 Alpha-Glucosidase Inhibitors
5.1.3 Dopamine D2 receptor agonist
5.1.3.1 Bromocriptin
5.1.4 SGLT-2 inhibitors
5.1.4.1 Invokana (Canagliflozin)
5.1.4.2 Jardiance (Empagliflozin)
5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.4.4 Suglat (Ipragliflozin)
5.1.5 DPP-4 inhibitors
5.1.5.1 Onglyza (Saxagliptin)
5.1.5.2 Tradjenta (Linagliptin)
5.1.5.3 Vipidia/Nesina(Alogliptin)
5.1.5.4 Galvus (Vildagliptin)
5.1.6 Sulfonylureas
5.1.6.1 Sulfonylureas
5.1.7 Meglitinides
5.1.7.1 Meglitinides
6. MARKET INDICATORS
6.1 Type-1 Diabetic Population
6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Takeda
7.1.2 Novo Nordisk
7.1.3 Pfizer
7.1.4 Eli Lilly
7.1.5 Janssen Pharmaceuticals
7.1.6 Astellas
7.1.7 Boehringer Ingelheim
7.1.8 Merck And Co.
7.1.9 AstraZeneca
7.1.10 Bristol Myers Squibb
7.1.11 Novartis
7.1.12 Sanofi
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
India Oral Anti-Diabetic Drug Industry Segmentation
Orally administered antihyperglycemic drugs reduce blood glucose levels. Diabetes medications are employed to manage diabetes mellitus by reducing the glucose concentration in the bloodstream. Apart from insulin, the majority of GLP receptor agonists (such as liraglutide, exenatide, and others) and pramlintide are taken orally, earning them the name of oral hypoglycemic agents or oral antihyperglycemic agents. India's Oral Anti-Diabetic Drug Market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.
| Oral Anti-diabetic Drugs (Value and Volume, 2017 - 2028) | ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
India Oral Anti-Diabetic Drug Market Research FAQs
How big is the India Oral Anti-Diabetic Drug Market?
The India Oral Anti-Diabetic Drug Market size is expected to reach USD 1.7 billion in 2024 and grow at a CAGR of 3.5% to reach USD 2.01 billion by 2029.
What is the current India Oral Anti-Diabetic Drug Market size?
In 2024, the India Oral Anti-Diabetic Drug Market size is expected to reach USD 1.7 billion.
Who are the key players in India Oral Anti-Diabetic Drug Market?
Sanofi, Eli Lilly, Astellas, Janseen and Astrazeneca are the major companies operating in the India Oral Anti-Diabetic Drug Market.
What years does this India Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?
In 2023, the India Oral Anti-Diabetic Drug Market size was estimated at USD 1.64 billion. The report covers the India Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the India Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
India Oral Anti-Diabetic Drug Industry Report
Statistics for the 2024 India Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. India Oral Anti-Diabetic Drug analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
